BPC-157 was classified as FDA Category 2 in 2023 and cannot be compounded by US pharmacies
It is a potential treatment approach with hopeful prospects
In fact, data from Bridelli et al
While oral and liposomal forms of Glutathione are accessible to patients, the effectiveness may not be transformative
Additionally, it has been shown that BPC 157, even with a single administration, managed to control right heart failure, increased P wave amplitude, tachycardia, and ST elevation caused by acute thrombotic coronary occlusion in mice (6, 7, 8)
Glutathione is only beneficial for lung conditions when it is delivered directly to the pulmonary tissue this is best achieved using a nebulizer This therapy may be helpful in the following conditions: Chronic congestion Chronic rhinitis Chronis sinusitis Post-viral cough Upper and lower respiratory tract infections Bronchitis Bronchiectasis Pneumonia Chronic otitis media with effusion COPD Cystic fibrosis Idiopathic pulmonary fibrosis Cigarette smoking detox-support Multiple chemical sensitivity disorder Non-sulfite sensitive asthma Farmers lung Who is a good candidate for this therapy
